S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
ASX:RAC

Race Oncology - RAC Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
76,322 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RAC stock logo

About Race Oncology (ASX:RAC) Stock

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Receive RAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAC Stock News Headlines

March 27, 2023 | proactiveinvestors.com.au
Race Oncology galvanised for new research and development thanks to A$1.48 million tax refund
March 24, 2023 | fool.com.au
Why is ASX All Ords healthcare share Race Oncology plummeting 10% today?
March 28, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 24, 2023 | msn.com
Why Block, Mincor, Race Oncology, and Weebit Nano shares are sinking today
March 14, 2023 | proactiveinvestors.com.au
Race Oncology poised for observational heart protection breast cancer trial
March 12, 2023 | proactiveinvestors.com
Race Oncology executes contract to begin observational heart protection breast cancer trial
March 2, 2023 | proactiveinvestors.com
Race Oncology higher on initiating collaboration to understand Zantrene’s cardioprotection mechanism
March 1, 2023 | finance.yahoo.com
Investing in Race Oncology (ASX:RAC) three years ago would have delivered you a 548% gain
March 28, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
February 21, 2023 | bbc.com
Breaking Through in Advanced Prostate Cancer
February 20, 2023 | msn.com
Race brings in new CEO as it looks beyond the clinic for potential partners and investors
February 11, 2023 | msn.com
Radioligand therapy, a 'game-changer' for cancer treatment, forces manufacturers to race against a ticking clock
February 9, 2023 | proactiveinvestors.com.au
Race Oncology is moving in the right direction: Pitt Street Research
February 1, 2023 | proactiveinvestors.com
Race Oncology receives human ethics approval for Zantrene trial
December 22, 2022 | proactiveinvestors.com.au
Race Oncology makes strong preclinical and clinical progress in 2022
December 22, 2022 | proactiveinvestors.com
Race Oncology to invest US$500,000 in University of Texas cancer imaging study
December 15, 2022 | proactiveinvestors.com.au
Race Oncology welcomes veteran Damian Clarke-Bruce as managing director/CEO
December 15, 2022 | proactiveinvestors.com.au
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
December 13, 2022 | proactiveinvestors.com
Race Oncology picks out Damian Clarke-Bruce to lead the company as it moves to ‘next stage of growth’
December 8, 2022 | proactiveinvestors.com.au
Race Oncology files human ethics application to commence cardioprotection breast cancer trial for Zantrene
December 4, 2022 | proactiveinvestors.com
Race Oncology appoints investment banker Daniel Sharp as independent non-executive director
November 24, 2022 | proactiveinvestors.com.au
Race Oncology welcomes positive pre-IND meeting for Zantrene
November 22, 2022 | proactiveinvestors.com
Race Oncology receives positive guidance on Zantrene at pre-IND meeting with FDA; shares rise
November 10, 2022 | proactiveinvestors.com.au
Race Oncology farewells CMO and appoints interim replacement ahead of recruitment process
October 17, 2022 | proactiveinvestors.com.au
Race Oncology receives bull case valuation of A$6.1 billion in Pitt Street Research’s initiation report
October 16, 2022 | finance.yahoo.com
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow
September 28, 2022 | proactiveinvestors.com
Race Oncology expands potential market with improved IV formulation for cancer drug Zantrene®
See More Headlines
Receive RAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAC Company Calendar

Last Earnings
2/27/2019
Today
3/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:RAC
CUSIP
N/A
CIK
N/A
Web
www.raceoncology.com
Phone
61 3 9097 1656
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.96%
Return on Assets
-18.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.90
Quick Ratio
23.71

Sales & Book Value

Annual Sales
$1.38 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
24.29
Book Value
A$0.19 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
161,310,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.61

Key Executives

  • Mr. Phillip R. Lynch
    CEO, MD & Director
  • Dr. Daniel Tillett
    Chief Scientific Officer & Exec. Director
  • Ms. Christina Manfre
    Chief Financial Officer
  • Dr. Ajay Duggal Dip Pharm Med
    MB ChB, MRCP, Interim Chief Medical Officer
  • Mr. Peter Gordon Webse B.Bus (Age 59)
    FCIS, FCPA, FGIA, M.A.I.C.D., MAICD, Company Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













RAC Stock - Frequently Asked Questions

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter.

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX).

What is Race Oncology's stock symbol?

Race Oncology trades on the ASX under the ticker symbol "RAC."

How much money does Race Oncology make?

Race Oncology (ASX:RAC) has a market capitalization of $0.00 and generates $1.38 million in revenue each year. The company earns $-10,790,000.00 in net income (profit) each year or A($0.07) on an earnings per share basis.

How can I contact Race Oncology?

The official website for the company is www.raceoncology.com. The company can be reached via phone at 61 3 9097 1656.

This page (ASX:RAC) was last updated on 3/28/2023 by MarketBeat.com Staff